Horizon Investments LLC Buys 18,143 Shares of BioMarin Pharmaceutical Inc. $BMRN

Horizon Investments LLC boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 22.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 99,681 shares of the biotechnology company’s stock after acquiring an additional 18,143 shares during the period. Horizon Investments LLC’s holdings in BioMarin Pharmaceutical were worth $5,924,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Viking Global Investors LP boosted its holdings in BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC boosted its holdings in BioMarin Pharmaceutical by 6.3% in the third quarter. AQR Capital Management LLC now owns 5,932,109 shares of the biotechnology company’s stock valued at $321,283,000 after acquiring an additional 351,536 shares in the last quarter. Capital Research Global Investors boosted its holdings in BioMarin Pharmaceutical by 547.5% in the third quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after acquiring an additional 2,145,717 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in BioMarin Pharmaceutical by 42.7% in the third quarter. Dimensional Fund Advisors LP now owns 2,245,186 shares of the biotechnology company’s stock valued at $121,597,000 after acquiring an additional 671,566 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in BioMarin Pharmaceutical by 0.4% in the third quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock valued at $90,028,000 after acquiring an additional 7,157 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

BMRN opened at $54.06 on Monday. The stock has a 50-day moving average price of $56.93 and a 200-day moving average price of $56.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.50. The firm has a market cap of $10.45 billion, a PE ratio of 30.37, a P/E/G ratio of 0.54 and a beta of 0.23. BioMarin Pharmaceutical Inc. has a 1 year low of $50.76 and a 1 year high of $66.28.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BMRN shares. Weiss Ratings upgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday. Canaccord Genuity Group lifted their price target on shares of BioMarin Pharmaceutical from $98.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Sanford C. Bernstein raised their price objective on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Barclays raised their price objective on BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. Finally, Wolfe Research reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $91.48.

Insider Activity

In other news, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. The trade was a 14.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. This represents a 17.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.